Loading stock data…
$1.32+0.08 (+6.45%)
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases.
Chemomab Therapeutics Ltd. in the Healthcare sector is trading at $1.32 with a market capitalization of $19M. Wall Street consensus targets $5.00 (1 analysts), implying a +278.8% move over the next 12 months. The stock is currently near its 52-week low of $1.05, remaining 26.3% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 22 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$2.24M↓ | -$1.85M↑ | -$1.97M↓ | -$1.84M↑ | -$2.26M |
| Net Income | -$2.17M↓ | -$1.77M↑ | -$1.87M↓ | -$1.74M↑ | -$2.06M |
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal anti...